Underlining a commitment to intensify the fight against HIV/AIDS, the National Department of Health has jointly awarded a R10bn three in one antiretroviral (ARV) medication tender to four pharmaceutical companies.
Under the tender’s terms, according to a statement from the department, the companies are to supply antiretroviral (ARV) medication to government for patients in South Africa for three years (2015 – 2017).
Sonke Pharmaceuticals has been awarded R3bn, Mylan Pharmaceuticals R2.8bn, Aspen Pharma R2.5bn, and Cipla Medpro R2bn.
There are over 2.7m people on ARV treatment in South Africa with about 1.5m receiving the fixed dose combination. The health department aims to have about 4.6m people on treatment by the end of 2016.
The simplified ARV medication enables people with HIV to take one tablet a day instead of three. The Department’s belief is that the roll-out of the fixed-dose combination (FDC) will assist a great deal in the management and treatment of HIV. It says FDC will improve compliance and reduce the risk of patients not complying with treatment dosage.
Employee Benefits That Actually Improve Retention Rates
July 17, 2026
